ARA-290 10mg
Non-Hematopoietic EPO Peptide for Neuropathy and Repair Research
ARA-290 is a peptide derived from the non-hematopoietic region of erythropoietin that activates the innate repair receptor without red blood cell stimulation. Research shows remarkable efficacy for neuropathic pain, small fiber neuropathy, and tissue repair.
Non-Hematopoietic EPO Peptide for Neuropathy and Repair Research
ARA-290 selectively activates the tissue-protective helix-B EPO receptor complex (EPOR/βcR) without the hematopoietic EPOR homodimer, enabling EPO's anti-inflammatory and repair properties without cardiovascular risks from RBC overproduction.
As one of the most studied compounds in the recovery & healing research space, ARA-290 has attracted sustained scientific interest across Neuropathy research, Nerve regeneration studies, Tissue repair protocols. Peer-reviewed evidence indicates that phase 2 trial: reduces neuropathic pain in sarcoidosis, which has positioned ARA-290 as a reference standard for researchers exploring neuropathy research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
ARA-290 Documented Benefits: 3 Documented Mechanisms
Neuropathic Pain Relief
Reduces small fiber neuropathy pain in clinical trials for conditions including sarcoidosis and diabetes.
Nerve Repair
Stimulates small fiber nerve regeneration, increasing intraepidermal nerve fiber density.
Anti-Inflammatory
Activates innate repair receptor to suppress inflammatory cytokine production without EPO's RBC effects.
How ARA-290 Works: Molecular Mechanism & Pathway
Helix-B surface peptide of EPO activating the EPOR/βcR innate repair receptor to suppress inflammation and stimulate tissue repair without hematopoietic effects.
The 3 primary research pathways identified for ARA-290 — Neuropathic Pain Relief, Nerve Repair, Anti-Inflammatory — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that increases IENF density in small fiber neuropathy, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, ARA-290's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
ARA-290 is routinely studied alongside BPC-157 and TB-500 in recovery & healing-focused compound panels. Researchers investigating neuropathy research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that no hematopoietic effects confirmed has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All ARA-290 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 2 trial: reduces neuropathic pain in sarcoidosis
- Increases IENF density in small fiber neuropathy
- No hematopoietic effects confirmed
Ideal For
- Neuropathy research
- Nerve regeneration studies
- Tissue repair protocols
- EPO pathway research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on ARA-290. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 2 trial: reduces neuropathic pain in sarcoidosis
Increases IENF density in small fiber neuropathy
No hematopoietic effects confirmed
Third-Party Verified Every Batch
Each vial of ARA-290 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
